SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical
company with a novel immunotherapy platform that produces
specifically targeted, high-potency, fully-human polyclonal
antibodies without the need for human donors, today announced the
appointment of Russell Beyer as chief financial officer (CFO),
effective September 20, 2021. Mr. Beyer will lead all aspects of
SAB’s financial operations and key supporting functions and will
work with the senior management team to drive SAB’s growth.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210928005435/en/
(Photo: Business Wire)
“We welcome Russell to the SAB team at an exciting time in the
company’s growth, as we advance SAB-185 into our first Phase 3
trial, as part of the NIH-sponsored ACTIV-2 trial protocol, based
on a promising DSMB interim analysis and continue development of
our broad pipeline spanning multiple diseases,” said Eddie J.
Sullivan, PhD, co-founder, president and CEO of SAB
Biotherapeutics. “We expect Russell’s extensive and varied
experience managing all aspects of financial reporting and
operations at global pharmaceutical companies will be invaluable as
we seek to scale our operations, broaden our scope and advance our
investigational products.”
Mr. Beyer brings more than 25 years of experience to SAB
overseeing financial functions at pharmaceutical and other Fortune
100 firms including AstraZeneca, Teva Pharmaceuticals and HBO. Most
recently, he was senior director of financial operations at Teva,
managing financial operations for shared services for the Americas.
Previously, Mr. Beyer held vice president positions at World Fuel
Services Corporation, a major marketer of fuel products, where he
helped the CEO manage major operational change. Earlier, Mr. Beyer
worked in financial management positions at the Clorox Company,
where he was CFO for Latin America; at HBO, where he was vice
president for finance and treasurer for Latin America; and at
AstraZeneca Pharmaceuticals, where he held positions of increasing
responsibility, including managing the merger of Astra and Zeneca
in Mexico as country CFO. Mr. Beyer began his career at the
Hewlett-Packard Company, where he ultimately served as a country
chief financial officer. Mr. Beyer received a BA degree from St.
Lawrence University and an MBA from the Simon School of Business at
the University of Rochester. He is a Certified Management
Accountant.
“I am excited to join the SAB team at this pivotal time, as the
company continues to develop a late-stage therapeutic candidate and
a promising, robust pipeline,” said Mr. Beyer. “SAB has developed
and optimized the technology and established sophisticated
infrastructure to produce polyclonal antibody therapeutics at
scale. I look forward to working with the team and contributing to
the company’s success as we embark on this next stage of the
company’s growth.”
On June 22, 2021, SAB announced a planned merger with Big
Cypress Acquisition Corp. The transaction is expected to close in
the fourth quarter of 2021.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage,
biopharmaceutical company advancing a new class of immunotherapies
leveraging fully human polyclonal antibodies. SAB has applied
advanced genetic engineering and antibody science to develop
transchromosomic (Tc) Bovine™ herds that produce fully-human
antibodies targeted at specific diseases, including infectious
diseases such as COVID-19 and influenza, immune system disorders
including type 1 diabetes and organ transplantation, and cancer.
SAB’s versatile DiversitAb™ platform is appliable to a wide range
of serious unmet needs in human diseases. It produces natural,
specifically targeted, high-potency, human polyclonal
immunotherapies. SAB is currently advancing multiple clinical
programs and has a number of collaborations with the US government
and global pharmaceutical companies. For more information on SAB,
visit: http://www.sabbiotherapeutics.com and follow @SABBantibody
on Twitter.
Forward-Looking Statements
Certain statements made herein that are not historical facts are
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“predict,” “potential,” “seem,” “seek,” “future,” “outlook” and
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, the development of SAB-185, and
the proposed business combination between Big Cypress and SAB.
These statements are based on the current expectations of SAB and
are not predictions of actual performance. These forward-looking
statements are provided for illustrative purposes only and are not
intended to serve as, and must not be relied on, by any investor as
a guarantee, an assurance, a prediction or a definitive statement
of fact or probability. Actual events and circumstances are
difficult or impossible to predict, will differ from assumption and
are beyond the control of SAB.
Additional Information and Where to Find It
In connection with the proposed business combination, Big
Cypress has filed with the SEC a definitive proxy
statement/prospectus. Big Cypress commenced mailing of the
definitive proxy statement/prospectus to its stockholders on
September 23, 2021. A proxy statement/prospectus will be sent to
all Big Cypress stockholders as of the record date of September 17,
2021. This communication is not a substitute for the Registration
Statement, the definitive proxy statement/final prospectus or any
other document that Big Cypress will send to its stockholders in
connection with the proposed business combination. Investors and
security holders of Big Cypress are advised to read the proxy
statement/prospectus in connection with Big Cypress’ solicitation
of proxies for its special meeting of stockholders to be held to
approve the proposed business combination (and related matters)
because the proxy statement/prospectus contains important
information about the proposed business combination and the parties
to the proposed business combination. Stockholders will also be
able to obtain copies of the proxy statement/prospectus, without
charge at the SEC’s website http://www.sec.gov or by directing a
request to ir@bigcypressaccorp.com.
Participants in the Solicitation
Big Cypress, SAB and their respective directors, executive
officers, other members of management, and employees, under SEC
rules, may be deemed to be participants in the solicitation of
proxies of Big Cypress’ stockholders in connection with the
proposed business combination. Investors and security holders may
obtain more detailed information regarding the names and interests
in the proposed business combination of Big Cypress’ directors and
officers in Big Cypress’ filings with the SEC including the
Registration Statement that has been submitted to the SEC by Big
Cypress, once finalized, which will include the proxy statement of
Big Cypress for the proposed business combination, and such
information and names of SAB’s directors and executive officers
also be in the Registration Statement submitted to the SEC by Big
Cypress, which will include the proxy statement of Big Cypress for
the proposed business combination.
Non-Solicitation
This press release is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the potential transaction and shall not constitute an
offer to sell or a solicitation of an offer to buy the securities
of Big Cypress or SAB, nor shall there be any sale of any such
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction. No offer of securities shall be made except by means
of a prospectus meeting the requirements of the Securities Act of
1933, as amended.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210928005435/en/
Melissa Ullerich +1 605-679-4609
mullerich@sabbiotherapeutics.com
Big Cypress Acquisition (NASDAQ:BCYP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Big Cypress Acquisition (NASDAQ:BCYP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024